Subependymal giant cell astrocytoma interventions: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Subependymal giant cell astrocytoma}} | {{Subependymal giant cell astrocytoma}} | ||
{{CMG}}, {{AE}}{{IO}} | |||
==Overview== | ==Overview== | ||
Latest revision as of 16:14, 8 November 2019
|
Subependymal giant cell astrocytoma Microchapters |
|
Differentiating Subependymal Giant Cell Astrocytoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Subependymal giant cell astrocytoma interventions On the Web |
|
American Roentgen Ray Society Images of Subependymal giant cell astrocytoma interventions |
|
Subependymal giant cell astrocytoma interventions in the news |
|
Risk calculators and risk factors for Subependymal giant cell astrocytoma interventions |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Ifeoma Odukwe, M.D. [2]
Overview
The mainstay of treatment for subependymal giant cell astrocytoma is surgery with medical therapy used in some cases.
Indications
The mainstay of treatment for subependymal giant cell astrocytoma is surgery with medical therapy used in some cases.[1]
References
- ↑ Campen CJ, Porter BE (2011). "Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update". Curr Treat Options Neurol. 13 (4): 380–5. doi:10.1007/s11940-011-0123-z. PMC 3130084. PMID 21465222.